Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-05-17T02:38:26.283Z Has data issue: false hasContentIssue false
  • English
  • Français

Managing Myasthenia Gravis with Eculizumab Monotherapy Through Pregnancy

Published online by Cambridge University Press:  01 August 2022

Xiaoyang Li Open the ORCID record for Xiaoyang Li [Opens in a new window]  and
Anahit Mehrabyan
Xiaoyang Li
Affiliation:
Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Anahit Mehrabyan*
Affiliation:
Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
*
Corresponding author: Dr. Anahit Mehrabyan, Department of Neurology, University of North Carolina School of Medicine, 170 Manning Drive, Campus Box 7025, Chapel Hill, NC, 27599-7025, USA. Email: mehrabac@neurology.unc.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Myasthenia gravisAcetylcholine receptor antibodyEculizumabMonotherapyPregnancy
Type
Letter to the Editor: New Observation
Information
Canadian Journal of Neurological Sciences , Volume 50 , Issue 5 , September 2023 , pp. 803 - 805
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Silvestri, NJ, Wolfe, GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014;15:167–78.CrossRefGoogle ScholarPubMed
Howard, JF, Utsugisawa, K, Benatar, M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16:976–86.CrossRefGoogle ScholarPubMed
Muppidi, S, Utsugisawa, K, Benatar, M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60:14–24.Google ScholarPubMed
Katyal, N, Narula, N, Govindarajan, R. Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis. J Neuromuscul Dis. 2021;8:287–94.Google ScholarPubMed
Pittock, SJ, Fujihara, K, Palace, J, et al. Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension. Mult Scler J. 2022;28:480–6.CrossRefGoogle ScholarPubMed
Alexion Pharmaceuticals, Inc. Soliris(eculizumab) injection; Prescribing information. Revised November 2020. https://alexion.com/Documents/Soliris_USPI.pdfGoogle Scholar
Levine, TD. Safety of an abbreviated transition period when switching from intravenous immunoglobulin to eculizumab in patients with treatment-refractory myasthenia gravis: a case series. Am J Case Rep. 2019;20:965–70.CrossRefGoogle ScholarPubMed
Vu, T, Harvey, B, Suresh, N, et al. Eculizumab during pregnancy in a patient with treatment-refractory myasthenia gravis: a case report. Case Rep Neurol. 2021;13:65–72.CrossRefGoogle Scholar
Sarno, L, Tufano, A, Maruotti, GM, et al. Eculizumab in pregnancy: a narrative overview. J Nephrol. 2019;32:17–25.CrossRefGoogle ScholarPubMed
Socié, G, Caby-Tosi, MP, Marantz, JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185:297–310.CrossRefGoogle ScholarPubMed